Trials / Completed
CompletedNCT00151762
Long-Term Study of Safety and Efficacy of WelChol® as an Additional Therapy in Patients With Type 2 Diabetes
A Multi-Center, 52-Week, Open-Label Extension Study (From Studies WEL-301, WEL-302, and WEL-303) to Evaluate the Long-Term Safety and Tolerability of WelChol® in Type 2 Diabetic Patients
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 780 (planned)
- Sponsor
- Daiichi Sankyo · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This extension study is designed to evaluate the long-term safety and tolerability of colesevelam hydrochloride (WelChol®) in patients with type 2 diabetes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Colesevelam hydrochloride |
Timeline
- Start date
- 2004-12-01
- Primary completion
- 2007-07-01
- Completion
- 2007-07-01
- First posted
- 2005-09-09
- Last updated
- 2008-01-09
Locations
64 sites across 3 countries: United States, Mexico, Peru
Source: ClinicalTrials.gov record NCT00151762. Inclusion in this directory is not an endorsement.